RxDoctor Payments Data

Manpreet Mundi, MD

Endocrinology, Diabetes & Metabolism · Rochester, MNNPI 1639359987

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $30,823 of the $38,589 with a category attached, or 79.9%. 6 manufacturers reported payments, led by Fresenius Kabi USA, LLC at 56.1% of the total.

$38,589in general payments, 2019–2025

Across 55 payments — averaging $701.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius Kabi USA, LLC$22K
  • Baxter Healthcare$6K
  • Nestle Healthcare Nutrition Inc.$5K
  • Alcresta Therapeutics, Inc.$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Novo Nordisk$2K
$399,684in research payments, 2019–2025

Across 30 payments — averaging $13,323 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nestle Healthcare Nutrition Inc.$299K
  • Vectivbio AG$97K
  • Fresenius Kabi USA, LLC$4K

What the payments were for

  • Consulting fees$30,82380%
  • Travel & lodging$5,52314%
  • Food & beverage$2,1766%
  • Education$670%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,589 in reported general payments places this provider in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

See all endocrinology, diabetes & metabolism providers in Minnesota

Medicare billing

Part B allowed, 2024
$36,798
Medicare patients
173
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$19,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,635$19,48522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.

Other endocrinology, diabetes & metabolism in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →